Assessment of the Safety of Glucocorticoid Regimens in Combination with Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study

Gerhardt Attard, Axel S. Merseburger, Wiebke Arlt, Cora N. Sternberg, Susan Feyerabend, Alfredo Berruti, Steven Joniau, L. Géczi, Florence Lefresne, Marjolein Lahaye, Florence Nave Shelby, Geneviève Pissart, Sue Chua, Robert J. Jones, Bertrand Tombal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Importance: Abiraterone acetate is combined with prednisone, 5 mg, twice daily for metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer. Understanding the physiological effects of these and other regimens is important. Objective: To evaluate the safety of abiraterone acetate with 4 glucocorticoid regimens. Design, Setting, and Participants: Open-label, randomized clinical trial (1:1:1:1) of 164 men with mCRPC from 22 hospitals in 5 countries who were randomly assigned to 1 of 4 intervention groups between June 2013 and October 2014. Analyses were conducted from August 2017 to June 2018. Interventions: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily (n = 41), 5 mg once daily (n = 41), 2.5 mg twice daily (n = 40), or dexamethasone, 0.5 mg, once daily (n = 42). Main Outcomes and Measures: Primary end point was no mineralocorticoid excess (grade ≥1 hypokalemia or grade ≥2 hypertension) through 24 weeks (6 cycles) from treatment. Results: Of 164 men (median [range] age, 70 [50-90] years) randomized to receive abiraterone acetate, 1000 mg, daily with prednisone, 5 mg, twice daily, once daily, or 2.5 mg twice daily, or dexamethasone, 0.5 mg, once daily, 24 (70.6%) of 34 patients (95% CI, 53.8%-83.2%), 14 (36.8%) of 38 patients (95% CI, 23.4%-52.7%), 21 (60.0%) of 35 patients (95% CI, 43.6%-74.4%), and 26 (70.3%) of 37 patients (95% CI, 54.2%-82.5%), respectively, had no mineralocorticoid excess. Plasma adrenocorticotrophic hormone and urinary mineralocorticoid metabolites after 8 weeks were higher with prednisone, 2.5 mg, twice daily and 5 mg once daily than with 5 mg twice daily or dexamethasone, 0.5 mg, once daily. The level of urinary glucocorticoid metabolites appeared higher in patients who did not meet the primary end point, regardless of glucocorticoid regimen. Total lean body mass decreased in the prednisone groups and total body fat increased in the prednisone, 5 mg, twice daily and dexamethasone groups. In the dexamethasone group, there was an increase in serum insulin and homeostatic model assessment of insulin resistance, while total bone mineral density decreased. In the prednisone, 5 mg, twice daily, 5 mg once daily, 2.5 mg twice daily, and dexamethasone groups, median radiographic progression-free survival was 18.5, 15.3, 12.8, and 26.6 months, respectively. Conclusions and Relevance: Abiraterone acetate with prednisone, 5 mg, twice daily or dexamethasone, 0.5 mg, once daily met the prespecified threshold for the primary end point (95% CI excluded 50% mineralocorticoid excess); abiraterone acetate with prednisone, 5 mg, once daily or 2.5 mg twice daily did not meet the threshold. Abiraterone acetate in combination with dexamethasone appeared to be particularly active but may be associated with adverse metabolic consequences. Trial Registration: ClinicalTrials.gov identifier: NCT01867710.

Original languageEnglish
JournalJAMA Oncology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Prednisone
Glucocorticoids
Dexamethasone
Safety
Mineralocorticoids
Castration
Prostatic Neoplasms
Abiraterone Acetate
Cancer Care Facilities
Hypokalemia
Bone Density
Adrenocorticotropic Hormone
Disease-Free Survival
Insulin Resistance
Adipose Tissue
Randomized Controlled Trials
Outcome Assessment (Health Care)
Insulin
Hypertension

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Assessment of the Safety of Glucocorticoid Regimens in Combination with Abiraterone Acetate : A Randomized, Open-Label Phase 2 Study. / Attard, Gerhardt; Merseburger, Axel S.; Arlt, Wiebke; Sternberg, Cora N.; Feyerabend, Susan; Berruti, Alfredo; Joniau, Steven; Géczi, L.; Lefresne, Florence; Lahaye, Marjolein; Shelby, Florence Nave; Pissart, Geneviève; Chua, Sue; Jones, Robert J.; Tombal, Bertrand.

In: JAMA Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Attard, G, Merseburger, AS, Arlt, W, Sternberg, CN, Feyerabend, S, Berruti, A, Joniau, S, Géczi, L, Lefresne, F, Lahaye, M, Shelby, FN, Pissart, G, Chua, S, Jones, RJ & Tombal, B 2019, 'Assessment of the Safety of Glucocorticoid Regimens in Combination with Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study', JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.1011
Attard, Gerhardt ; Merseburger, Axel S. ; Arlt, Wiebke ; Sternberg, Cora N. ; Feyerabend, Susan ; Berruti, Alfredo ; Joniau, Steven ; Géczi, L. ; Lefresne, Florence ; Lahaye, Marjolein ; Shelby, Florence Nave ; Pissart, Geneviève ; Chua, Sue ; Jones, Robert J. ; Tombal, Bertrand. / Assessment of the Safety of Glucocorticoid Regimens in Combination with Abiraterone Acetate : A Randomized, Open-Label Phase 2 Study. In: JAMA Oncology. 2019.
@article{9981b9610f79438687ed086d7e8ed539,
title = "Assessment of the Safety of Glucocorticoid Regimens in Combination with Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study",
abstract = "Importance: Abiraterone acetate is combined with prednisone, 5 mg, twice daily for metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer. Understanding the physiological effects of these and other regimens is important. Objective: To evaluate the safety of abiraterone acetate with 4 glucocorticoid regimens. Design, Setting, and Participants: Open-label, randomized clinical trial (1:1:1:1) of 164 men with mCRPC from 22 hospitals in 5 countries who were randomly assigned to 1 of 4 intervention groups between June 2013 and October 2014. Analyses were conducted from August 2017 to June 2018. Interventions: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily (n = 41), 5 mg once daily (n = 41), 2.5 mg twice daily (n = 40), or dexamethasone, 0.5 mg, once daily (n = 42). Main Outcomes and Measures: Primary end point was no mineralocorticoid excess (grade ≥1 hypokalemia or grade ≥2 hypertension) through 24 weeks (6 cycles) from treatment. Results: Of 164 men (median [range] age, 70 [50-90] years) randomized to receive abiraterone acetate, 1000 mg, daily with prednisone, 5 mg, twice daily, once daily, or 2.5 mg twice daily, or dexamethasone, 0.5 mg, once daily, 24 (70.6{\%}) of 34 patients (95{\%} CI, 53.8{\%}-83.2{\%}), 14 (36.8{\%}) of 38 patients (95{\%} CI, 23.4{\%}-52.7{\%}), 21 (60.0{\%}) of 35 patients (95{\%} CI, 43.6{\%}-74.4{\%}), and 26 (70.3{\%}) of 37 patients (95{\%} CI, 54.2{\%}-82.5{\%}), respectively, had no mineralocorticoid excess. Plasma adrenocorticotrophic hormone and urinary mineralocorticoid metabolites after 8 weeks were higher with prednisone, 2.5 mg, twice daily and 5 mg once daily than with 5 mg twice daily or dexamethasone, 0.5 mg, once daily. The level of urinary glucocorticoid metabolites appeared higher in patients who did not meet the primary end point, regardless of glucocorticoid regimen. Total lean body mass decreased in the prednisone groups and total body fat increased in the prednisone, 5 mg, twice daily and dexamethasone groups. In the dexamethasone group, there was an increase in serum insulin and homeostatic model assessment of insulin resistance, while total bone mineral density decreased. In the prednisone, 5 mg, twice daily, 5 mg once daily, 2.5 mg twice daily, and dexamethasone groups, median radiographic progression-free survival was 18.5, 15.3, 12.8, and 26.6 months, respectively. Conclusions and Relevance: Abiraterone acetate with prednisone, 5 mg, twice daily or dexamethasone, 0.5 mg, once daily met the prespecified threshold for the primary end point (95{\%} CI excluded 50{\%} mineralocorticoid excess); abiraterone acetate with prednisone, 5 mg, once daily or 2.5 mg twice daily did not meet the threshold. Abiraterone acetate in combination with dexamethasone appeared to be particularly active but may be associated with adverse metabolic consequences. Trial Registration: ClinicalTrials.gov identifier: NCT01867710.",
author = "Gerhardt Attard and Merseburger, {Axel S.} and Wiebke Arlt and Sternberg, {Cora N.} and Susan Feyerabend and Alfredo Berruti and Steven Joniau and L. G{\'e}czi and Florence Lefresne and Marjolein Lahaye and Shelby, {Florence Nave} and Genevi{\`e}ve Pissart and Sue Chua and Jones, {Robert J.} and Bertrand Tombal",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2019.1011",
language = "English",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Assessment of the Safety of Glucocorticoid Regimens in Combination with Abiraterone Acetate

T2 - A Randomized, Open-Label Phase 2 Study

AU - Attard, Gerhardt

AU - Merseburger, Axel S.

AU - Arlt, Wiebke

AU - Sternberg, Cora N.

AU - Feyerabend, Susan

AU - Berruti, Alfredo

AU - Joniau, Steven

AU - Géczi, L.

AU - Lefresne, Florence

AU - Lahaye, Marjolein

AU - Shelby, Florence Nave

AU - Pissart, Geneviève

AU - Chua, Sue

AU - Jones, Robert J.

AU - Tombal, Bertrand

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Importance: Abiraterone acetate is combined with prednisone, 5 mg, twice daily for metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer. Understanding the physiological effects of these and other regimens is important. Objective: To evaluate the safety of abiraterone acetate with 4 glucocorticoid regimens. Design, Setting, and Participants: Open-label, randomized clinical trial (1:1:1:1) of 164 men with mCRPC from 22 hospitals in 5 countries who were randomly assigned to 1 of 4 intervention groups between June 2013 and October 2014. Analyses were conducted from August 2017 to June 2018. Interventions: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily (n = 41), 5 mg once daily (n = 41), 2.5 mg twice daily (n = 40), or dexamethasone, 0.5 mg, once daily (n = 42). Main Outcomes and Measures: Primary end point was no mineralocorticoid excess (grade ≥1 hypokalemia or grade ≥2 hypertension) through 24 weeks (6 cycles) from treatment. Results: Of 164 men (median [range] age, 70 [50-90] years) randomized to receive abiraterone acetate, 1000 mg, daily with prednisone, 5 mg, twice daily, once daily, or 2.5 mg twice daily, or dexamethasone, 0.5 mg, once daily, 24 (70.6%) of 34 patients (95% CI, 53.8%-83.2%), 14 (36.8%) of 38 patients (95% CI, 23.4%-52.7%), 21 (60.0%) of 35 patients (95% CI, 43.6%-74.4%), and 26 (70.3%) of 37 patients (95% CI, 54.2%-82.5%), respectively, had no mineralocorticoid excess. Plasma adrenocorticotrophic hormone and urinary mineralocorticoid metabolites after 8 weeks were higher with prednisone, 2.5 mg, twice daily and 5 mg once daily than with 5 mg twice daily or dexamethasone, 0.5 mg, once daily. The level of urinary glucocorticoid metabolites appeared higher in patients who did not meet the primary end point, regardless of glucocorticoid regimen. Total lean body mass decreased in the prednisone groups and total body fat increased in the prednisone, 5 mg, twice daily and dexamethasone groups. In the dexamethasone group, there was an increase in serum insulin and homeostatic model assessment of insulin resistance, while total bone mineral density decreased. In the prednisone, 5 mg, twice daily, 5 mg once daily, 2.5 mg twice daily, and dexamethasone groups, median radiographic progression-free survival was 18.5, 15.3, 12.8, and 26.6 months, respectively. Conclusions and Relevance: Abiraterone acetate with prednisone, 5 mg, twice daily or dexamethasone, 0.5 mg, once daily met the prespecified threshold for the primary end point (95% CI excluded 50% mineralocorticoid excess); abiraterone acetate with prednisone, 5 mg, once daily or 2.5 mg twice daily did not meet the threshold. Abiraterone acetate in combination with dexamethasone appeared to be particularly active but may be associated with adverse metabolic consequences. Trial Registration: ClinicalTrials.gov identifier: NCT01867710.

AB - Importance: Abiraterone acetate is combined with prednisone, 5 mg, twice daily for metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer. Understanding the physiological effects of these and other regimens is important. Objective: To evaluate the safety of abiraterone acetate with 4 glucocorticoid regimens. Design, Setting, and Participants: Open-label, randomized clinical trial (1:1:1:1) of 164 men with mCRPC from 22 hospitals in 5 countries who were randomly assigned to 1 of 4 intervention groups between June 2013 and October 2014. Analyses were conducted from August 2017 to June 2018. Interventions: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily (n = 41), 5 mg once daily (n = 41), 2.5 mg twice daily (n = 40), or dexamethasone, 0.5 mg, once daily (n = 42). Main Outcomes and Measures: Primary end point was no mineralocorticoid excess (grade ≥1 hypokalemia or grade ≥2 hypertension) through 24 weeks (6 cycles) from treatment. Results: Of 164 men (median [range] age, 70 [50-90] years) randomized to receive abiraterone acetate, 1000 mg, daily with prednisone, 5 mg, twice daily, once daily, or 2.5 mg twice daily, or dexamethasone, 0.5 mg, once daily, 24 (70.6%) of 34 patients (95% CI, 53.8%-83.2%), 14 (36.8%) of 38 patients (95% CI, 23.4%-52.7%), 21 (60.0%) of 35 patients (95% CI, 43.6%-74.4%), and 26 (70.3%) of 37 patients (95% CI, 54.2%-82.5%), respectively, had no mineralocorticoid excess. Plasma adrenocorticotrophic hormone and urinary mineralocorticoid metabolites after 8 weeks were higher with prednisone, 2.5 mg, twice daily and 5 mg once daily than with 5 mg twice daily or dexamethasone, 0.5 mg, once daily. The level of urinary glucocorticoid metabolites appeared higher in patients who did not meet the primary end point, regardless of glucocorticoid regimen. Total lean body mass decreased in the prednisone groups and total body fat increased in the prednisone, 5 mg, twice daily and dexamethasone groups. In the dexamethasone group, there was an increase in serum insulin and homeostatic model assessment of insulin resistance, while total bone mineral density decreased. In the prednisone, 5 mg, twice daily, 5 mg once daily, 2.5 mg twice daily, and dexamethasone groups, median radiographic progression-free survival was 18.5, 15.3, 12.8, and 26.6 months, respectively. Conclusions and Relevance: Abiraterone acetate with prednisone, 5 mg, twice daily or dexamethasone, 0.5 mg, once daily met the prespecified threshold for the primary end point (95% CI excluded 50% mineralocorticoid excess); abiraterone acetate with prednisone, 5 mg, once daily or 2.5 mg twice daily did not meet the threshold. Abiraterone acetate in combination with dexamethasone appeared to be particularly active but may be associated with adverse metabolic consequences. Trial Registration: ClinicalTrials.gov identifier: NCT01867710.

UR - http://www.scopus.com/inward/record.url?scp=85068252645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068252645&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.1011

DO - 10.1001/jamaoncol.2019.1011

M3 - Article

C2 - 31246234

AN - SCOPUS:85068252645

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -